<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">RUDN Journal of Medicine</journal-id><journal-title-group><journal-title xml:lang="en">RUDN Journal of Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российского университета дружбы народов. Серия: Медицина</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-0245</issn><issn publication-format="electronic">2313-0261</issn><publisher><publisher-name xml:lang="en">Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">23810</article-id><article-id pub-id-type="doi">10.22363/2313-0245-2020-24-2-145-155</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ONCOLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОНКОЛОГИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Immunohistochemical study of P53 protein expression in different prostate cancer Gleason grading groups</article-title><trans-title-group xml:lang="ru"><trans-title>Иммуногистохимическое исследование экспрессии белка P53 в аденокарциномах предстательной железы различной степени злокачественности</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kudryavtsev</surname><given-names>G. Y.</given-names></name><name xml:lang="ru"><surname>Кудрявцев</surname><given-names>Г. Ю.</given-names></name></name-alternatives><email>kgosha@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kudryavtseva</surname><given-names>L. V.</given-names></name><name xml:lang="ru"><surname>Кудрявцева</surname><given-names>Л. В.</given-names></name></name-alternatives><email>kgosha@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mikhaleva</surname><given-names>L. M.</given-names></name><name xml:lang="ru"><surname>Михалева</surname><given-names>Л. М.</given-names></name></name-alternatives><email>kgosha@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kudryavtseva</surname><given-names>Y. Y.</given-names></name><name xml:lang="ru"><surname>Кудрявцева</surname><given-names>Я. Ю.</given-names></name></name-alternatives><email>kgosha@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Solovyeva</surname><given-names>N. A.</given-names></name><name xml:lang="ru"><surname>Соловьева</surname><given-names>Н. А.</given-names></name></name-alternatives><email>kgosha@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Osipov</surname><given-names>V. A.</given-names></name><name xml:lang="ru"><surname>Осипов</surname><given-names>В. А.</given-names></name></name-alternatives><email>kgosha@mail.ru</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Babichenko</surname><given-names>I. I.</given-names></name><name xml:lang="ru"><surname>Бабиченко</surname><given-names>И. И.</given-names></name></name-alternatives><email>kgosha@mail.ru</email><xref ref-type="aff" rid="aff6"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Peoples’ Friendship University of Russia (RUDN University)</institution></aff><aff><institution xml:lang="ru">Российский университет дружбы народов</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">War Veteran Hospital № 2</institution></aff><aff><institution xml:lang="ru">Госпиталь для ветеранов войн № 2 Департамента здравоохранения города Москвы</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Research Institute of Human Morphology Moscow</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт морфологии человека</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Peoples’ Friendship University of Russia (RUDN University)</institution></aff><aff><institution xml:lang="ru">Госпиталь для ветеранов войн № 2 Департамента здравоохранения города Москвы</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">War Veteran Hospital № 2</institution></aff><aff><institution xml:lang="ru">Российский университет дружбы народов</institution></aff></aff-alternatives><aff id="aff6"><institution>Peoples’ Friendship University of Russia (RUDN University)</institution></aff><pub-date date-type="pub" iso-8601-date="2020-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2020</year></pub-date><volume>24</volume><issue>2</issue><issue-title xml:lang="en">VOL 24, NO2 (2020)</issue-title><issue-title xml:lang="ru">ТОМ 24, №2 (2020)</issue-title><fpage>145</fpage><lpage>155</lpage><history><date date-type="received" iso-8601-date="2020-05-27"><day>27</day><month>05</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Kudryavtsev G.Y., Kudryavtseva L.V., Mikhaleva L.M., Kudryavtseva Y.Y., Solovyeva N.A., Osipov V.A., Babichenko I.I.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, Кудрявцев Г.Ю., Кудрявцева Л.В., Михалева Л.М., Кудрявцева Я.Ю., Соловьева Н.А., Осипов В.А., Бабиченко И.И.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Kudryavtsev G.Y., Kudryavtseva L.V., Mikhaleva L.M., Kudryavtseva Y.Y., Solovyeva N.A., Osipov V.A., Babichenko I.I.</copyright-holder><copyright-holder xml:lang="ru">Кудрявцев Г.Ю., Кудрявцева Л.В., Михалева Л.М., Кудрявцева Я.Ю., Соловьева Н.А., Осипов В.А., Бабиченко И.И.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.rudn.ru/medicine/article/view/23810">https://journals.rudn.ru/medicine/article/view/23810</self-uri><abstract xml:lang="en"><p>Prostate cancer (PC) remains an urgent public health problem, especially in developed countries. The use of immunohistochemical research methods in addition to the morphological classification of prostate adenocarcinomas allows a more accurate diagnosis and prognosis of the disease. The aim of the study is to identify isoforms of P53 using clones of mouse antibodies (D-07 and Y5; Epitomics, USA) in prostate cancer with different proliferative activity and the degree of malignancy. Materials and Methods: The work included surgical material for prostate resection and prostatectomy, as well as biopsy specimens (56 cases in total). An immunohistochemical study was carried out with the Ki-67 marker, as well as with mouse monoclonal antibodies (D-07 and Y5) to the P53 protein, interacting with its “wild” and mutant isoforms. The significance of the difference in the samples was determined using the Mann-Whitney U-test, correlation relationships were determined using the Spearman coefficient. Results: Expression of P53 upon interaction with antibodies D-07 and Y5 was determined in 56.3% and 39.6%, respectively. A statistically significant direct correlation was found between the severity of P53 expression when interacting with Y5 antibodies and the degree of tumor differentiation (rs = 0.567, p &lt;0.05), as well as between the expression level of this protein and tumor proliferative activity (rs = 0.698, p &lt;0.05). Conclusion: Antibodies of clone D-07, interacting with both wild and mutant isoforms of P53 protein, show positive expression in adenocarcinomas of all degrees. Expression of the mutant P53 protein is most pronounced in low-differentiated carcinomas and correlates with high proliferative activity of tumor cells, which may be associated with a loss in the induction of P53-dependent apoptosis.</p></abstract><trans-abstract xml:lang="ru"><p>Актуальность. Рак предстательной железы (РПЖ) остается актуальной проблемой в сфере здравоохранения, в особенности в развитых странах. Использование иммуногистохимических методов исследования в дополнение к морфологической классификации аденокарцином предстательной железы позволяет точнее поставить диагноз и определить прогноз заболевания. Целью исследования является выявление изоформ P53 с помощью клонов мышиных антител (D-07 и Y5; Epitomics, США) в РПЖ с различной пролиферативной активностью и степенью злокачественности. Материалы и методы: В работу вошел операционный материал резекции предстательной железы и простатэктомии, а также биоптаты (всего 56 случаев). Проведено иммуногистохимическое исследование с маркером Ki-67, а также с мышиными моноклональными антителами (D-07 и Y5) к белку P53, взаимодействующими с его «дикой» и мутантной изоформами. Достоверность различия выборок определяли с помощью U-критерия Манна-Уитни, корреляционные взаимоотношения определяли с помощью коэффициента Спирмена. Результаты: Экспрессия P53 при взаимодействии с антителами D-07 и Y5 определена в 56,3% и 39,6% соответственно. Обнаружена статистически значимая прямая корреляционная связь между выраженностью экспрессии P53 при взаимодействии с антителами Y5 и степенью дифференцировки опухоли (rs=0,567, p&lt;0.05), а также между уровнем экспрессии этого белка и пролиферативной активностью опухоли (rs=0,698, p&lt;0.05). Заключение: Антитела клона D-07, взаимодействуя как с «дикой», так и мутантной изоформой белка P53, показывают положительную экспрессию в аденокарциномах всех степеней злокачественности. Экспрессия мутантного белка P53, наиболее выражена в низкодифференцированных карциномах и коррелирует с высокой пролиферативной активностью опухолевых клеток, что может быть связано с утратой индукции P53-зависимого апоптоза.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Ki-67</kwd><kwd>P53</kwd><kwd>prostate cancer</kwd><kwd>adenocarcinoma</kwd><kwd>Ki-67</kwd><kwd>P53</kwd><kwd>Gleason index</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак предстательной железы</kwd><kwd>аденокарцинома простаты</kwd><kwd>индекс Глисона</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA. Jemal. A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68:394–424.</mixed-citation><mixed-citation xml:lang="ru">Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA. Jemal. A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68:394-424.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Ferlay J EM, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Published 2018. Accessed 14 September, 2018.</mixed-citation><mixed-citation xml:lang="ru">Ferlay EM, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Published 2018. Accessed 14 September, 2018.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Kaprin A.D., Starinskij V.V., Petrova G.V., redaktory. Zlokachestvennye novoobrazovaniya v Rossii v 2018 godu (zabolevaemost’ i smertnost’). M.: MNIOI im. P.A. Gercena – filial FGBU «NMIC radiologii» Minzdrava Rossii, 2019. 250 p.</mixed-citation><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Петрова Г.В., редакторы. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 250 с.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov VI, Hussey SK, et al. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124(13):2801–14.</mixed-citation><mixed-citation xml:lang="ru">Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov VI, Hussey SK, et al. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124(13):2801-2814.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Lu Y, Liu Y, Zeng J, He Y, Peng Q, Deng Y, et al. Association of p53 codon 72 polymorphism with prostate cancer: An update meta-analysis. Tumour Biol. 2014;35: 3997–4005.</mixed-citation><mixed-citation xml:lang="ru">Lu Y, Liu Y, Zeng J, He Y, Peng Q, Deng Y et al. Association of p53 codon 72 polymorphism with prostate cancer: An update meta-analysis. Tumour Biol. 2014;35: 3997-4005.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2017; 170(6):1062–78.</mixed-citation><mixed-citation xml:lang="ru">Kastenhuber ER, Lowe SW. Putting p 53 in Context. Cell. 2017; 170(6):1062-1078.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Lozano G, Levine AJ, editors. The p53 Protein: From Cell Regulation to Cancer. Cold Spring Harbor, NY: Cold Spring Harb. Lab; 2016. 245 p.</mixed-citation><mixed-citation xml:lang="ru">Lozano G, Levine AJ, editors. The p 53 Protein: From Cell Regulation to Cancer. Cold Spring Harbor, NY: Cold Spring Harb. Lab; 2016.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Valdez JM, Nichols KE, Kesserwan C. Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. British Journal of Haematology, 2016; 176(4), 539–52.</mixed-citation><mixed-citation xml:lang="ru">Valdez JM, Nichols KE, Kesserwan C. Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. British Journal of Haematology, 2016; 176(4), 539-552.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304–17.</mixed-citation><mixed-citation xml:lang="ru">Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304-317.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Kruiswijk F, Labuschagne CF, Vousden KH. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol. 2015;16:393–405.</mixed-citation><mixed-citation xml:lang="ru">Kruiswijk F, Labuschagne CF, Vousden KH. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol. 2015;16:393-405.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Missaoui N, Abdelkarim SB, Mokni M, Hmissa S. Prognostic factors of prostate cancer in Tunisian men: immunohistochemical study. Asian Pac J Cancer Prev. 2016;17:2655–62.</mixed-citation><mixed-citation xml:lang="ru">Missaoui N, Abdelkarim SB, Mokni M, Hmissa S. Prognostic factors of prostate cancer in Tunisian men: immunohistochemical study. Asian Pac J Cancer Prev. 2016;17:2655.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Chevrier M, Bobbala D, Villalobos-Hernandez A, Khan MG, Ramanathan S, Saucier C, et al. Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer. BMC Cancer. 2017;17:157–61.</mixed-citation><mixed-citation xml:lang="ru">Chevrier M, Bobbala D, Villalobos-Hernandez A, Khan MG, Ramanathan S, Saucier C, et al. Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer. BMC Cancer. 2017;17:157.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Zellweger T, Gunther S, Zlobec I, Savic S, Sauter G, Moch H, et al. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer. 2009;124:2116–23.</mixed-citation><mixed-citation xml:lang="ru">Zellweger T, Gunther S, Zlobec I, Savic S, Sauter G, Moch H, et al. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer. 2009;124:2116-23.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Kaur H, Paul M, Manjari M, Sharma S, Bhasin TS, Mannan R. Ki-67 and p53 immunohistochemical expression in prostate carcinoma: An experience from a tertiary care centre of North India. Annals of Path and Lab Med. 2016;3(6):509–16.</mixed-citation><mixed-citation xml:lang="ru">Kaur H, Paul M, Manjari M, Sharma S, Bhasin TS, Mannan R. Ki-67 and p53 immunohistochemical expression in prostate carcinoma: An experience from a tertiary care centre of North India. Annals of Path and Lab Med. 2016;3(6):509-16.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Fantony JJ, Howard LE, Csizmadi I, et al. Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study. Biomark Med. 2018;12(7):727–36.</mixed-citation><mixed-citation xml:lang="ru">Fantony JJ, Howard LE, Csizmadi I, et al. Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study. Biomark Med. 2018;12(7):727-736.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Berlin A, Castro-Mesta JF, Rodriguez-Romo L, Hernandez-Barajas D, González-Guerrero J F, Rodríguez-Fernández IA. Prognostic role of Ki-67 score in localized prostate cancer: A systematic review and meta-analysis. Ur Onco. 2017; 35(8): 499–506.</mixed-citation><mixed-citation xml:lang="ru">Berlin A, Castro-Mesta JF, Rodriguez-Romo L, Hernandez-Barajas D, González-Guerrero JF, Rodríguez-Fernández IA. Prognostic role of Ki-67 score in localized prostate cancer: A systematic review and meta-analysis. Ur Onco. 2017; 35(8): 499-506.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Kudryavtsev GY, Kudryavtseva LV, Mikhaleva LM, Babichenko II. Immunohistochemical Study of Tumor Cells Proliferative Activity at Different Graduations. RUDN Journal of Medicine. 2019 Dec; 23 (4): 364–72.</mixed-citation><mixed-citation xml:lang="ru">Кудрявцев Г.Ю., Кудрявцева Л.В., Михалева Л.М., Бабиченко И.И. Иммуногистохимическое исследование пролиферативной активности опухолевых клеток при различных градациях аденокарциномы предстательной железы. Вестник РУДН. Серия: Медицина. 2019;23(4): 364-372.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Verma R, Gupta V, Singh J, et al. Significance of p53 and Ki-67 expression in prostate cancer. Urol Ann. 2015;7(4):488–93.</mixed-citation><mixed-citation xml:lang="ru">Verma R, Gupta V, Singh J, et al. Significance of p53 and ki-67 expression in prostate cancer. Urol Ann. 2015;7(4):488-493.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
